全文获取类型
收费全文 | 4647篇 |
免费 | 400篇 |
国内免费 | 147篇 |
专业分类
耳鼻咽喉 | 60篇 |
儿科学 | 39篇 |
妇产科学 | 107篇 |
基础医学 | 846篇 |
口腔科学 | 137篇 |
临床医学 | 253篇 |
内科学 | 446篇 |
皮肤病学 | 98篇 |
神经病学 | 281篇 |
特种医学 | 206篇 |
外国民族医学 | 6篇 |
外科学 | 379篇 |
综合类 | 794篇 |
现状与发展 | 1篇 |
预防医学 | 129篇 |
眼科学 | 32篇 |
药学 | 297篇 |
2篇 | |
中国医学 | 87篇 |
肿瘤学 | 994篇 |
出版年
2023年 | 33篇 |
2022年 | 70篇 |
2021年 | 112篇 |
2020年 | 113篇 |
2019年 | 132篇 |
2018年 | 133篇 |
2017年 | 155篇 |
2016年 | 135篇 |
2015年 | 162篇 |
2014年 | 278篇 |
2013年 | 231篇 |
2012年 | 262篇 |
2011年 | 329篇 |
2010年 | 315篇 |
2009年 | 340篇 |
2008年 | 281篇 |
2007年 | 254篇 |
2006年 | 272篇 |
2005年 | 227篇 |
2004年 | 210篇 |
2003年 | 179篇 |
2002年 | 130篇 |
2001年 | 135篇 |
2000年 | 99篇 |
1999年 | 81篇 |
1998年 | 71篇 |
1997年 | 55篇 |
1996年 | 59篇 |
1995年 | 48篇 |
1994年 | 40篇 |
1993年 | 26篇 |
1992年 | 23篇 |
1991年 | 19篇 |
1990年 | 16篇 |
1989年 | 21篇 |
1988年 | 14篇 |
1987年 | 13篇 |
1986年 | 16篇 |
1985年 | 18篇 |
1984年 | 18篇 |
1983年 | 13篇 |
1982年 | 10篇 |
1981年 | 11篇 |
1980年 | 5篇 |
1979年 | 5篇 |
1978年 | 2篇 |
1977年 | 7篇 |
1976年 | 6篇 |
1975年 | 3篇 |
1974年 | 2篇 |
排序方式: 共有5194条查询结果,搜索用时 31 毫秒
991.
目的: 检测P16和Ki-67在尖锐湿疣组织、邻近外观正常组织中的表达.方法: 免疫组化SP法检测43例CA组织及其邻近外观正常组织中P16和Ki-67的表达,并以18例正常组织做对照.结果:在CA组织、邻近外观正常组织以及正常对照组织中,P16的阳性表达率分别为44.19%、16.28%、11.11%,CA组与后两组间差异均有统计学意义(P<0.01和P<0.05),后两组之间差异无统计学意义(P>0.05).Ki-67的阳性表达率分别为88.37%、27.91%、27.78%,CA组与后两组间差异均有统计学意义(P<0.01),后两组之间差异无统计学意义(P>0.05).结论: P16和Ki-67在CA组织中表达增高,导致细胞周期失控,并促使细胞异常增殖. 相似文献
992.
目的探讨胃癌组织中NET-1、Ki67和CD34表达的临床病理学意义。方法应用免疫组化二步法检测86例胃癌组织中NET-1、Ki67和CD34的表达,对三指标均阳性病例进行免疫组化三重标记法双染方法,原位检测三指标的表达特点和毗邻关系。所有病例随访60月以上。结果胃癌组织中 NET-1、Ki67和CD34高表达分别为56.98%、74.42%和62.79%,三指标阳性表达呈显著正相关(P<0.01)。三指标高表达分别与肿瘤临床分期呈正相关(均P<0.05),与患者生存率呈负相关(均P<0.05), 其3、5年生存率均显著低于相应的低表达组或阴性组(P<0.05,P<0.01)。 NET-1、Ki67高表达分别与肿瘤分化呈负相关(均P<0.01)。NET-1、CD34高表达分别与癌浸润深度、淋巴结转移呈正相关(均P<0.05)。结论NET-1、Ki67和CD34在胃癌组织中高表达与癌细胞增殖、癌血管形成和预后差有关。 相似文献
993.
目的研究不同胃黏膜病变组织中胃泌素和Ki-67的表达,探讨胃泌素在胃癌发生中的作用。方法96例不同胃黏膜病变组织来自胃镜活检标本。采用免疫组织化学染色技术检测胃泌素和Ki-67表达。结果胃泌素在浅表性胃炎(CSG)、萎缩性胃炎(CAG)、肠化生(IM)、异型增生(Dy)和胃癌(GC)中表达的阳性率分别为58.8 %、30.0%、57.9 %、68.2%和77.8%,CAG组与GC组比较,差异有统计学意义(P<0.05);从CSG→GC,Ki 67增殖指数(PI)呈逐渐递增趋势,且从CAG→GC,胃泌素的表达与PI呈正相关(P<0.05)。结论胃泌素在萎缩性胃炎中呈低表达,在胃黏膜肠化生、异型增生及胃癌中,表达异常增高;胃泌素与胃癌的发生有关。 相似文献
994.
Ki-67、p53蛋白在乳腺癌组织的表达及临床意义 总被引:5,自引:1,他引:4
目的探讨Ki-67、p53蛋白在乳腺癌及癌旁组织中的表达及两者之间的关系和临床意义。方法应用免疫组化S-P法检测80例乳腺癌组织及其癌旁的正常乳腺组织中Ki-67、p53蛋白的表达,分析其与临床病理因素的关系及两者的相关性。结果80例乳腺癌组织中Ki-67蛋白阳性表达率为63.8%,高于癌旁乳腺组织8.8%(P〈0.05),其表达与患者年龄、肿瘤大小、ER、PR表达无关,与肿瘤的分期、腋窝淋巴结转移、C-erbB-2表达相关。乳腺癌组织p53蛋白阳性表达率为68.8%,高于癌旁乳腺组织11.3%((P〈0.05),其表达与年龄、肿瘤大小、分期、ER、PR表达无关,与腋窝淋巴结转移、C-erbB-2表达相关。Ki-67蛋白与p53蛋白表达之间无关。结论Ki-67、p53蛋白可通过抑制细胞凋亡,对乳腺癌发生和发展起重要作用,是判断乳腺癌生物学行为、预测转移趋势有价值的参考指标。 相似文献
995.
乳腺癌淋巴结转移与Ki67、VEGF表达的相关性及其临床意义 总被引:3,自引:1,他引:2
目的探讨乳腺癌淋巴结转移与VEGF(血管内皮生长因子)、K167表达的相关关系及其临床意义。方法采用免疫组化法检测125例乳腺癌组织中VEGF、Ki67的表达以及淋巴结转移的情况。结果腋窝淋巴结转移阳性率为72.8%.VEGF、Ki67表达阳性率分别为:56.8%和74.4%,VEGF与Ki67表达呈正相关(P〈0.01),淋巴结转移与Ki67表达无显著相关(P〉0.05),而与VEGF表达呈正相关(P〈0.01):结论VEGF和Ki67在肿瘤的发生和发展过程中协同作用;Ki67及VEGF的表达与乳腺淋巴结转移是影响乳腺癌预后的重要因素。 相似文献
996.
997.
Aparna A. Kamat MD Donna Coffey MD William M. Merritt MD Elizabeth Nugent MD Diana Urbauer PhD Yvonne G. Lin MD Creighton Edwards MD Russell Broaddus MD Robert L. Coleman MD Anil K. Sood MD 《Cancer》2009,115(12):2684-2692
BACKGROUND:
EphA2 is a tyrosine kinase receptor in the ephrin family that is implicated in oncogenesis and angiogenesis. The objective of the current investigation was to study the role of EphA2 in endometrial cancer and its relation to steroid hormone receptor expression.METHODS:
EphA2, estrogen receptor (ER), progesterone receptor (PR), and Ki‐67 expression levels were evaluated using immunohistochemistry in 139 endometrioid endometrial carcinoma (EEC) samples and in 10 benign endometrial samples. Samples were scored by 2 investigators who were blinded to clinical outcome. The results were correlated with clinicopathologic characteristics using univariate and multivariate analysis. A P value <.05 was considered statistically significant.RESULTS:
High expression of EphA2 was detected in 48% of EEC samples versus 10% of benign samples. EphA2 overexpression was associated significantly with high disease stage (P = .04), high tumor grade (P = .003), increased depth of myometrial invasion (P = .05), low ER expression (P = .01), low PR expression (P = .006), and high Ki‐67 expression (P = .04). Low ER and PR expression levels were associated with high tumor grade, positive lymph nodes, high Ki‐67 expression, and high EphA2 expression. On univariate analysis of all patients, high EphA2 expression was associated significantly with shorter disease‐specific survival (DSS) (P < .001). On multivariate analysis, age (P < .001), high disease stage (P = .002), and high EphA2 expression (P = .04) were independent predictors of poor DSS.CONCLUSIONS:
EphA2 overexpression was associated with aggressive phenotypic features in EEC and was associated inversely with ER and PR expression. Thus, EphA2 may be an important therapeutic target, especially in patients with hormone receptor‐negative endometrial carcinoma. Cancer 2009. © 2009 American Cancer Society. 相似文献998.
Silva SD Perez DE Alves FA Nishimoto IN Pinto CA Kowalski LP Graner E 《Oral oncology》2008,44(5):484-490
The oncoprotein ErbB2 (HER-2/neu) is a tyrosine kinase cell surface receptor overexpressed in several human malignancies, including oral squamous cell carcinoma (OSCC). ErbB2 was recently shown to regulate the expression of fatty acid synthase (FAS), a multifunctional enzyme complex responsible for the de novo biosynthesis of saturated fatty acids. Here we evaluated the relationship between the immunohistochemical expression of ErbB2, FAS, and Ki-67 with the clinicopathologic characteristics of tongue squamous cell carcinoma (SCC). One hundred and two patients with tongue SCC treated from 1990 to 1995 were studied. Clinical and treatment data were obtained from the medical records and histopathological features revised. Paraffin-embedded tissues were submitted to standard immunohistochemical reactions for ErbB2, FAS and Ki-67. A strong positive correlation between ErbB2 labeling at the cell membrane and FAS expression was found in the tongue SCC samples (p < 0.0001). The intracytoplasmatic expression of ErbB2 as well as Ki-67 nuclear staining were significantly associated with a high risk of recurrence by predicting both disease free survival (log-rank test, p = 0.0096 and p = 0.0047, respectively) and overall survival (log-rank test, p = 0.0029 and p = 0.0001, respectively). Taken together, our results suggest that the immunolocalization of ErbB2 at the cell surface of malignant oral keratinocytes is linked to FAS expression whereas the intracytoplasmatic ErbB2 or Ki-67 staining predict high risk of recurrence of tongue SCC. 相似文献
999.
1000.
A dose response study of inhaled nitric oxide in hypoxic respiratory failure in preterm infants 总被引:2,自引:0,他引:2
Ahluwalia J Tooley J Cheema I Sweet DG Curley AE Halliday HL Field D Al'malik H Annamalai S Midgley P Hardy P Tomlin K Elbourne D 《Early human development》2006,82(7):477-483
BACKGROUND: Inhaled nitric oxide (iNO) is used widely in newborn infants with hypoxic respiratory failure, despite the known and theoretical toxicity of iNO, and a relative lack of information about appropriate doses. AIM: To determine whether a dose-response relationship existed for iNO in preterm infants. DESIGN: A four-period, four-dose, cross-over design was used with iNO given for 15 min in a randomised sequence in concentrations of 5, 10, 20 and 40 parts per million (ppm), with a minimum 5 min wash-out period. Data on ventilatory, blood gas and other physiological measurements were recorded before and at the end of each period. The relationship of clinical response with iNO dose and period was analysed using multivariate regression. SUBJECTS: Infants with gestational age < 34 weeks and < 28 days postnatal age with hypoxic respiratory failure were recruited. OUTCOME MEASURE: A clinically significant dose-response was defined as a rise in the post-ductal arterial oxygen tension (PaO(2)) of at least 3 kPa. RESULTS: Thirteen infants were recruited. At trial entry, ten were < 3 days of age; 11 were being treated with high frequency oscillatory ventilation; median (inter-quartile range) gestational age 27 (25-29) weeks; birthweight 983 (765-1120) g; oxygenation index 27.1 (21.8-28.8). Six infants (46%) showed a clinically significant response. After adjusting for period and patient effect, no evidence for an overall dose effect was identified (likelihood ratio test, p=0.34). CONCLUSION: No evidence of a dose-response relationship with iNO was found in this study of very preterm infants with respiratory failure. 相似文献